LINCOLNSHIRE Ill.--(BUSINESS WIRE)--Jul 11 2007 - BioSantePharmaceu...The new results are based on a study using a hemagglutinationinhibiti... We are working to create a vaccine using our BioVant that wouldbe gi... According to a paper published in the New England Journal ofMedicine...BioSante's preclinical study objective was to determine whetherBioVan...

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSante
Pharmaceuticals, Inc. (Amex: BPA) today announced new positive
results demonstrating that its calcium phosphate (CaP)
nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as an
effective vaccine adjuvant for the development of a dose sparing
vaccine against H5N1 avian flu, widely known as bird flu.

The new results are based on a study using a hemagglutination
inhibition assay (HAI), which showed the clear adjuvanting effect
of BioVant. After a prime and one booster of
BioVant-H5N1-combination-vaccine, the immune response in a rodent
model was four-fold that of the H5N1 antigen alone. The study was
done with 3 micrograms of H5N1 antigen in each vaccine dose.
Earlier this year, the U.S. Food and Drug Administration approved
an H5N1 vaccine that uses 90 micrograms of H5N1 antigen by itself
given in each of two doses.

"We are working to create a vaccine using our BioVant that would
be given at lower doses per injection yet still confer a higher
level of immunity than the currently approved vaccine," said
Stephen M. Simes, president and chief executive officer of
BioSante. "These HAI study results confirm the BioVant antibody
results previously reported and add to the data base for a
potential BioSante improved BioVant adjuvanted bird flu
vaccine."

"According to a paper published in the New England Journal of
Medicine, the currently approved bird-flu vaccine without an
adjuvant by a European drug company is effective only at high doses
(90 micrograms per dose) and only 54 percent of subjects produced
the desired immune response. We believe a BioVant-adjuvanted H5N1
vaccine may use less antigen per dose and protect a higher
percentage of the population." Mr. Simes continued.

BioSante's preclinical study objective was to determine whether
BioVant could enhance the body's natural immune response to the
H5N1 viral antigen, the cause
of bird flu. At the start of the
trial, mice received either the H5N1 antigen alone or in a
formulation with BioVant. A booster immunization was administered
after two weeks. Results indicated that the administration of a
BioVant-H5N1 formulation stimulated production of high titers of
H5N1-specific antibodies, which were significantly higher than H5N1
alone. Anti-avian flu antibody levels continued to increase over
the entire study period, suggesting good duration of immunity.

Avian flu refers to a large group of different influenza viruses
that primarily affect birds. While the vast majority of these
viruses do not affect humans, the H5N1 strain already has made the
jump from birds to humans and in fact, has infected 310 people and
killed 190 since the outbreak of the disease in 2003, and more than
250 million chickens have been killed to stop the spread of the
virus. Farmers and poultry producers already have suffered losses
in the billions of dollars. There is widespread concern that a
strain of avian flu will mutate into a new form that is contagious
among humans. Since there is currently no truly effective vaccine
available to protect humans from H5N1 and humans do not have
antibodies to fight this new virus strain, there is significant
risk of a pandemic.

An adjuvant is a substance that, when added to a vaccine,
enhances the vaccine's effectiveness by stimulating an immune
system response. In multiple studies, BioVant has been shown to be
safe and cause minimal dose-dependent inflammation at the injection
site, and has been shown to both prevent the manifestation of
allergic response, and, to effectively 'switch off' established
Th2-T-cell-associated allergic disease.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver
bio-identical estradiol and testosterone. B
ioSante's lead products
include Elestrin(TM) (estradiol gel) developed through FDA approval
by BioSante indicated for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause, marketed in the U.S.
by Bradley Pharmaceuticals, Inc., BioSante's licensee, and
LibiGel(R) (transdermal testosterone gel) in Phase III development
by BioSante for the treatment of female sexual dysfunction (FSD).
Also in development is Bio-T-Gel(TM), a testosterone gel for male
hypogonadism, and an oral contraceptive using BioSante patented
technology. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion and for oral
contraceptives approximately $3.0 billion. The company also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including hepatitis B, avian flu and biodefense vaccines
for toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration. Additional
information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The statements regarding BioSante contained in this news release
that are not historical in nature, particularly those that utilize
terminology such as "may," "will," "should," "would," "likely,"
"expects," "anticipates," "estimates," "believes," "plans,"
"hopes," or comparable terminology, are forward-looking statements.
Forward-looking statements are based on current expectations and
assumptions, and entail various risks and uncertainties that could
cause actual results to differ materially from those expressed in
such forward-looking statements. Important factors known to
BioSante that could cause actual results to differ materially from
those expressed in such forward-looking statements include the
difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving mar
ket acceptance, the
success of clinical testing, and other factors identified and
discussed from time to time in BioSante's filings with the
Securities and Exchange Commission, including those factors
discussed in BioSante's most recent annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q, which discussions also
are incorporated herein by reference. All forward-looking
statements speak only as of the date of this news release. BioSante
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.

(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...

(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...

(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...

(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...

(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...

(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...